Skip to main content
Fig. 6 | Stem Cell Research & Therapy

Fig. 6

From: CD106 is a novel mediator of bone marrow mesenchymal stem cells via NF-κB in the bone marrow failure of acquired aplastic anemia

Fig. 6

Expression and function of NF-κB (p65). a Left panel: NanoPro NF-κB profiles in BM mesenchymal stem cells (MSCs) from healthy controls (N) and aplastic anemia (AA) patients. Right panel: Quantitation of NF-κB in BM-MSCs from AA patients and healthy controls (n = 4). b Immunofluorescence on CD106 (red), NF-κB (green), and nuclei (blue) in unsorted MSCs from healthy controls. c The expression of NF-κB fluorescence was found in CD106+ BM-MSCs and CD106 BM-MSCs from healthy controls. d The expression of CD106 was not found in BM-MSCs from healthy controls when blocked by a NF-κB specific inhibitor. e The ratio of NF-κB by tumor necrosis factor alpha (TNF-α) nuclear transfer stimulated at 1 h. g Immunofluorescence on NF-κB (green) and nuclei (blue) in CD106+ BM-MSCs and CD106 BM-MSCs from healthy controls. f The ratio of NF-κB by lipopolysaccharide (LPS) nuclear transfer stimulated at 1 h and 2 h. h Immunofluorescence on NF-κB (red) and nuclei (blue) in CD106+ BM-MSCs and CD106 BM-MSCs from healthy controls. *P<0.05 **P < 0.01, ***P < 0.001

Back to article page